期刊文献+

颅内动脉粥样硬化性狭窄病人行Wingspan支架术后再狭窄的危险因素分析及临床策略研究 被引量:2

下载PDF
导出
摘要 目的评估颅内动脉粥样硬化性狭窄(ICAS)病人行Wingspan支架治疗后出现支架内再狭窄(ISR)的危险因素以及临床策略分析。方法回顾性分析2015年11月—2017年11月于沧州市人民医院行Wingspan支架治疗的ICAS病人45例。运用HR-MRI进行颅内动脉狭窄扫描。运用TOF-MRA重建并确定血管结构和动脉狭窄位置。使用美国国立卫生研究院卒中量表(NIHSS)评分评估脑卒中严重程度。分别于术后1个月、3个月、6个月复查头部核磁共振(MRI)和核磁共振血管造影(MRA)检查,评估病人的临床不良事件,并记录短暂性脑缺血发作和脑梗死的复发情况,根据随访6个月后有无ISR分为再狭窄组和无狭窄组。运用多因素分析评估发生ISR的相关危险因素。结果最终再狭窄组12例,无狭窄组33例。术后发生ISR的时间为(4.2±0.5)个月。两组性别、年龄、吸烟史、合并症、实验室检查、NIHSS评分等比较差异无统计学意义(P>0.05)。再狭窄组中大脑中动脉狭窄比例较高(P=0.004),再狭窄组血管狭窄长度(P=0.008)和血管狭窄程度均较无狭窄组更重(P<0.001)。多因素分析结果显示,血管狭窄长度[OR=3.560,95%CI(1.138,8.816),P<0.001]和血管狭窄程度[OR=3.157,95%CI(1.235,7.968),P<0.001]是支架术后发生ISR的独立危险因素。结论血管狭窄长度和血管狭窄程度是Wingspan支架术后再狭窄的危险因素。临床工作中应完善术前及术后的危险因素评估,及时规避相关危险因素,对于严重狭窄病人需选择合适的治疗方案,尽量减少ISR的发生。
出处 《中西医结合心脑血管病杂志》 2020年第11期1810-1814,共5页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献5

二级参考文献67

  • 1Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet, 2014, 383(9914): 333-341 .
  • 2Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl ] Med Overseas Ed, 2011,365( 11): 993-1003.
  • 3Chimowitz MI, Lynn MI, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl JMed Overseas Ed, 2005, 352(13): 1305-1316.
  • 4Zaidat OO, Klucznik R, Alexander MJ, et al. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology, 2008, 70(17): 1518-1524.
  • 5Fiorella D, Levy El, Turk AS, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke, 2007, 38(3):881-887.
  • 6Li l, Zhao ZW, Gao GD, et al. Wingspan stenting with modified predilation for symptomatic middle cerebral artery stenosis. Catheter Cardiovasc Interv, 2011, 78(2): 286-293.
  • 7Fiorella DJ, Turk AS, Levy EI, et al. U.S. Wingspan Registry: 12-month follow-up results. Stroke, 2011, 42(7): 1976-1981.
  • 8Gandini R, Chiaravalloti A, Pampana E, et aL IntracraniaI atheromatous disease treatment with the Wingspan stent system: evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid- term results. Clin Neurol Neurosurg, 2013, 115(6): 741-747.
  • 9Yu SC, Leung TW, Lee KT, et al. Angioplasty and stenting of intracranial atherosclerosis with the Wingspan system: 1-year clinical and radiological outcome in a single Asian center. ] Neurointerv Surg, 2014,6(2): 96-102.
  • 10Nahab F, Lynn MJ, Kasner SE, et al. Risk factors associated with major cerebrovascular complications after intracranial stenting. Neurology, 2009, 72(23): 2014-2019.

共引文献56

同被引文献17

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部